| Literature DB >> 33968231 |
Novshaba Nazeer1, Phani Bhushan Ivaturi2.
Abstract
Introduction Ear, nose and throat (ENT)pathologies can present with proptosis as the early manifestation. The majority of ENT pathologies present with ocular manifestations, due to close anatomical relationship. Objective To study proptosis in ENT disorders in terms of etiology, pathogenesis, and management. Methods The present article is a prospective study conducted at a tertiary care center, in Telangana, India. Patients presenting with proptosis secondary to ENT disorders were thoroughly evaluated and subjected to surgical exploration after providing a signed informed consent. Results Sixty cases of proptosis secondary to ENT disorders have been reported. The most common cause was sinonasal squamous cell carcinoma followed by juvenile nasopharyngeal angiofibroma and allergic fungal rhinosinusitis. Conclusion Many ENT disorders can present with proptosis. Proptosis needs to be evaluated completely for proper management and to limit the morbidity associated with it. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: Graves'disease; ethmoid; orbit; proptosis
Year: 2020 PMID: 33968231 PMCID: PMC8096516 DOI: 10.1055/s-0040-1709986
Source DB: PubMed Journal: Int Arch Otorhinolaryngol ISSN: 1809-4864
Fig. 1Graph depicting age distribution of study population.
Etiology distribution of study population
| Etiology | N; % |
|---|---|
|
| |
| Nasal vestibulitis | 1; 2% |
| Acute bacterial rhinosinusitis | 3; 5% |
| Allergic fungal rhinosinusitis | 6; 10% |
| Acute invasive fungal sinusitis | 1; 2% |
| Fungal granuloma | 3; 5% |
| Wegener granulomatosis | 1; 2% |
| Ethmoid mucocele | 2; 3% |
| Sinonasalschwannoma | 2; 3% |
| Inverted papilloma | 1; 2% |
| Frontal sinus osteoma | 1; 2% |
| Fibrous dysplasia of maxilla | 3; 5% |
| Fibrous dysplasia of ethmoid | 1; 2% |
| Sinonasalsquamous cell carcinoma | 12; 20% |
| Sinonasaladenocarcinoma | 2; 3% |
| Sinonasaladenoid cystic carcinoma | 2; 3% |
| Sinonasalembryonal rhabdomyosarcoma | 1; 2% |
| Olfactory neuroblastoma | 1; 2% |
|
| |
| Juvenile nasopharyngeal angiofibroma | 7; 11% |
| Nasopharyngeal carcinoma | 4; 6% |
|
| |
| Graves' disease | 6; 10% |
Etiopathogenesis of study population
| Etiology | Pathogenesis |
|---|---|
|
| |
| Nasal vestibulitis | Vascular (1; 2%) |
| Acute bacterial rhinosinusitis | Vascular (2; 3%) |
| Allergic fungal rhinosinusitis | Compression (6; 10%) |
| Acute invasive fungal sinusitis | Erosion (1; 2%) |
| Fungal granuloma | Compression (1; 2%) |
| Wegener granulomatosis | Erosion (1; 2%) |
| Ethmoid mucocele | Compression (1; 2%) |
| Sinonasalschwannoma | Compression (1; 2%) |
| Inverted papilloma | Erosion (1; 2%) |
| Frontal sinus osteoma | Compression (1; 2%) |
| Fibrous dysplasia of maxilla | Compression (3; 5%) |
| Fibrous dysplasia of ethmoid | Compression (1; 2%) |
| Sinonasalsquamous cell carcinoma | Erosion (12; 20%) |
| Sinonasaladenocarcinoma | Erosion (2; 3%) |
| Sinonasaladenoid cystic carcinoma | Erosion (2; 3%) |
| Sinonasalembryonal rhabdomyosarcoma | Erosion (1; 2%) |
| Olfactory neuroblastoma | Erosion (1; 2%) |
|
| |
| Juvenile nasopharyngeal angiofibroma | Erosion (1; 2%) |
| Nasopharyngeal carcinoma | Erosion (2; 3%) |
|
| |
| Graves' disease | Increased intraconal fat (6; 10%) |
|
| |
Non-surgical treatment distribution of study population
| Etiology | Non-surgical management |
|---|---|
|
| |
| Nasal vestibulitis | IV antibiotics (1; 2%) |
| Acute bacterial rhinosinusitis | IV antibiotics (3; 5%) |
| Allergic fungal rhinosinusitis | Intranasal steroids (6, 10%) |
| Acute invasive fungal sinusitis | IV amphotericin B (1; 2%) |
| Fungal granuloma | IV amphotericin B (3; 5%) |
| Wegener granulomatosis | Oral steroids (1, 2%) |
| Ethmoid mucocele | – |
| Sinonasal schwannoma | – |
| Inverted papilloma | – |
| Frontal sinus osteoma | – |
| Fibrous dysplasia of maxilla | – |
| Fibrous dysplasia of ethmoid | – |
| Sinonasal squamous cell carcinoma | Radiotherapy |
| Sinonasal adenocarcinoma | – |
| Sinonasal adenoid cystic carcinoma | Postoperative radiotherapy |
| Sinonasal embryonal rhabdomyosarcoma | Chemotherapy |
| Olfactory neuroblastoma | Postoperative radiotherapy |
|
| |
| Juvenile nasopharyngeal angiofibroma |
|
| Nasopharyngeal carcinoma | Radiotherapy (4; 6%) |
|
| |
| Graves' disease | Antithyroid drugs (6; 10%) |
|
| |
Abbreviation: IV, intravenous.
Surgical treatment of study population
| Etiology | Surgery |
|---|---|
|
| |
| Nasal vestibulitis | Incision &drainage (1; 2%) |
| Acute bacterial rhinosinusitis | Functional endoscopic sinus surgery (3; 5%) |
| Allergic fungal rhinosinusitis | Functional endoscopic sinus surgery (6; 10%) |
| Acute invasive fungal sinusitis | Endoscopic sinus surgery and debridement (1; 2%) |
| Fungal granuloma | Endoscopic sinus surgery (3; 5%) |
| Wegener granulomatosis | Endoscopic sinus surgery (1; 2%) |
| Ethmoid mucocele | Functional endoscopic sinus surgery (2; 3%) |
| Sinonasalschwannoma | Endoscopic resection (2;3%) |
| Inverted papilloma | Endoscopic resection (1; 2%) |
| Frontal sinus osteoma | Bicoronalincision and excision (1; 2%) |
| Fibrous dysplasia of maxilla | Lateral rhinotomy &paring (3; 5%) |
| Fibrous dysplasia of ethmoid | Lynch-Howarth external approach and removal (1,; 2%) |
| Sinonasalsquamous cell carcinoma | Total maxillectomy (2; 3%) |
| Sinonasaladenocarcinoma | Total maxillectomy (2; 3%) |
| Sinonasaladenoid cystic carcinoma | Total maxillectomy (2; 3%) |
| Sinonasalembryonal rhabdomyosarcoma | – |
| Olfactory neuroblastoma | Endoscopic resection (1; 2%) |
|
| |
| Juvenile nasopharyngeal angiofibroma | Endoscopic surgery with coblation (2; 3%) |
| Nasopharyngeal carcinoma | – |
|
| |
| Graves' disease | Orbital decompression (2; 3%) |
|
| |